<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="4255">
  <stage>Registered</stage>
  <submitdate>8/11/2013</submitdate>
  <approvaldate>8/11/2013</approvaldate>
  <nctid>NCT01984424</nctid>
  <trial_identification>
    <studytitle>Goal Achievement After Utilizing an Anti-PCSK9 Antibody in Statin Intolerant Subjects-3</studytitle>
    <scientifictitle>A Double-blind, Randomized, Multicenter Study to Evaluate the Safety and Efficacy of Evolocumab, Compared With Ezetimibe, in Hypercholesterolemic Subjects Unable to Tolerate an Effective Dose of a HMG-CoA Reductase Inhibitor Due to Muscle Related Side Effects</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>20120332</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Hyperlipidemia</healthcondition>
    <conditioncode>
      <conditioncode1>Metabolic and Endocrine</conditioncode1>
      <conditioncode2>Other metabolic disorders</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - Part A, Atorvastatin
Other interventions - Part A, Placebo (administered orally)
Treatment: drugs - Part B, Evolocumab
Other interventions - Part B, Placebo (administered orally)
Treatment: drugs - Part B, Ezetimibe
Other interventions - Part B, Placebo (administered subcutaneously)
Treatment: drugs - Part C, Evolocumab

Experimental: Part A (two-period cross-over), Arm 1 - Atorvastatin

Placebo Comparator: Part A (two-period cross-over), Arm 2 - Placebo

Experimental: Part B, Arm 1 - Evolocumab

Active Comparator: Part B, Arm 2 - Ezetimbe

Experimental: Part C, Arm 1 - Evolocumab


Treatment: drugs: Part A, Atorvastatin
Subjects will receive atorvastatin daily

Other interventions: Part A, Placebo (administered orally)
Subjects will receive oral placebo daily

Treatment: drugs: Part B, Evolocumab
Subjects will receive subcutaneous evolocumab every month

Other interventions: Part B, Placebo (administered orally)
Subjects will receive oral placebo every day

Treatment: drugs: Part B, Ezetimibe
Subjects will receive oral ezetimibe daily

Other interventions: Part B, Placebo (administered subcutaneously)
Subjects will receive subcutaneous placebo every month.

Treatment: drugs: Part C, Evolocumab
Subjects will receive subcutaneous evolocumab every 2 weeks or monthly

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
    <interventioncode>Other interventions interventions</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Mean percent change from baseline in low density lipoprotein-cholesterol - Mean percent change from baseline in low density lipoprotein-cholesterol</outcome>
      <timepoint>22 and 24 Weeks</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Percent change from baseline in low density lipoprotein-cholesterol - Percent change from baseline in low density lipoprotein-cholesterol</outcome>
      <timepoint>24 Weeks</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Mean change from baseline in low density lipoprotein-cholesterol - Mean change from baseline in low density lipoprotein-cholesterol</outcome>
      <timepoint>22 and 24 Weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change from baseline in low density lipoprotein-cholesterol - Change from baseline in low density lipoprotein-cholesterol</outcome>
      <timepoint>24 Weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Mean low density lipoprotein-cholesterol response (low density lipoprotein-cholesterol &lt; 70 mg/dL [1.8 mmol/L]) - Mean low density lipoprotein-cholesterol response (low density lipoprotein-cholesterol &lt; 70 mg/dL [1.8 mmol/L])</outcome>
      <timepoint>22 and 24 Weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Low density lipoprotein-cholesterol response (low density lipoprotein-cholesterol &lt; 70 mg/dL [1.8 mmol/L]) - Low density lipoprotein-cholesterol response (low density lipoprotein-cholesterol &lt; 70 mg/dL [1.8 mmol/L])</outcome>
      <timepoint>24 Weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Mean percent change from baseline in total cholesterol - Mean percent change from baseline in total cholesterol</outcome>
      <timepoint>22 and 24 Weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Percent change from baseline in total cholesterol - Percent change from baseline in total cholesterol</outcome>
      <timepoint>24 Weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Mean percent change from baseline in non-high density lipoprotein-cholesterol - Mean percent change from baseline in non-high density lipoprotein-cholesterol</outcome>
      <timepoint>22 and 24 Weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Percent change from baseline in non-high density lipoprotein-cholesterol - Percent change from baseline in non-high density lipoprotein-cholesterol</outcome>
      <timepoint>24 Weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Mean percent change from baseline in apolipoprotein B - Mean percent change from baseline in apolipoprotein B</outcome>
      <timepoint>22 and 24 Weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Percent change from baseline in apolipoprotein B - Percent change from baseline in apolipoprotein B</outcome>
      <timepoint>24 Weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Mean percent change from baseline in the total cholesterol/high density lipoprotein-cholesterol ratio - Mean percent change from baseline in the total cholesterol/high density lipoprotein-cholesterol ratio</outcome>
      <timepoint>22 and 24 Weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Percent change from baseline in the total cholesterol/high density lipoprotein-cholesterol ratio - Percent change from baseline in the total cholesterol/high density lipoprotein-cholesterol ratio</outcome>
      <timepoint>24 Weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Mean percent change from baseline in apolipoprotein B/apolipoprotein A1 ratio - Mean percent change from baseline in apolipoprotein B/apolipoprotein A1 ratio</outcome>
      <timepoint>22 and 24 Weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Percent change from baseline in apolipoprotein B/apolipoprotein A1 ratio - Percent change from baseline in apolipoprotein B/apolipoprotein A1 ratio</outcome>
      <timepoint>24 Weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Mean percent change from baseline in lipoprotein (a) - Mean percent change from baseline in lipoprotein (a)</outcome>
      <timepoint>22 and 24 Weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Percent change from baseline in lipoprotein (a) - Percent change from baseline in lipoprotein (a)</outcome>
      <timepoint>24 Weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Mean percent change from baseline in triglycerides - Mean percent change from baseline in triglycerides</outcome>
      <timepoint>22 and 24 Weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Percent change from baseline in triglycerides - Percent change from baseline in triglycerides</outcome>
      <timepoint>24 Weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Mean percent change from baseline in high density lipoprotein-cholesterol - Mean percent change from baseline in high density lipoprotein-cholesterol</outcome>
      <timepoint>22 and 24 Weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Percent change from baseline in high density lipoprotein-cholesterol - Percent change from baseline in high density lipoprotein-cholesterol</outcome>
      <timepoint>24 Weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Mean percent change from baseline in very low density lipoprotein-cholesterol - Mean percent change from baseline in very low density lipoprotein-cholesterol</outcome>
      <timepoint>22 and 24 Weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Percent change from baseline in very low density lipoprotein-cholesterol - Percent change from baseline in very low density lipoprotein-cholesterol</outcome>
      <timepoint>24 Weeks</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Male or female = 18 to = 80 years of age

          -  Subject not at LDL-C goal

          -  History of statin intolerance

          -  Lipid lowering therapy has been stable prior to enrolment for at least 4 weeks

          -  Fasting triglycerides = 400 mg/dL</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>80</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  NYHA III or IV heart failure

          -  Uncontrolled cardiac arrhythmia

          -  Uncontrolled hypertension

          -  Type 1 diabetes

          -  Poorly controlled type 2 diabetes

          -  Uncontrolled hypothyroidism or hyperthyroidism</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1>The people receiving the treatment/s</masking1>
    <masking2>The people administering the treatment/s</masking2>
    <masking3>The people assessing the outcomes</masking3>
    <masking4>The people analysing the results/data</masking4>
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 3</phase>
    <anticipatedstartdate />
    <actualstartdate>10/12/2013</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>511</actualsamplesize>
    <recruitmentstatus>Active, not recruiting</recruitmentstatus>
    <anticipatedlastvisitdate>14/11/2017</anticipatedlastvisitdate>
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>NSW,QLD,SA</recruitmentstate>
    <hospital>Research Site - Camperdown</hospital>
    <hospital>Research Site - Woolloongabba</hospital>
    <hospital>Research Site - Ashford</hospital>
    <postcode>2015 - Camperdown</postcode>
    <postcode>4102 - Woolloongabba</postcode>
    <postcode>5035 - Ashford</postcode>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>California</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Georgia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Illinois</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Kansas</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Maryland</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Michigan</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Minnesota</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Missouri</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New York</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>North Carolina</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Ohio</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Pennsylvania</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>South Carolina</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Texas</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>British Columbia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Ontario</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Quebec</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Czechia</country>
      <state>Hradec Kralove</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Czechia</country>
      <state>Praha 2</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Czechia</country>
      <state>Praha 4</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Denmark</country>
      <state>Aarhus N</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Denmark</country>
      <state>Glostrup</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Nantes Cedex 1</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Paris Cedex 13</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Vénissieux</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Berlin</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Köln</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>München</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Bologna</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Cagliari</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Cinisello Balsamo (MI)</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Ferrara</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Perugia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Pisa</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Netherlands</country>
      <state>Amsterdam</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Netherlands</country>
      <state>Rotterdam</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Netherlands</country>
      <state>Zwijndrecht</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Christchurch</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Norway</country>
      <state>Oslo</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Norway</country>
      <state>Ålesund</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>South Africa</country>
      <state>Gauteng</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>South Africa</country>
      <state>Western Cape</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Birmingham</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Glasgow</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Newcastle upon Tyne</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Amgen</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>The study is divided into 3 parts (A, B, C). Part A is a double-blind, placebo-controlled,
      two-period cross-over rechallenge of atorvastatin 20 mg. Part B is a 24-week double-blind,
      double-dummy comparison of evolocumab and ezetimibe. Part C is a 2-year open-label evolocumab
      extension. The primary hypothesis is that evolocumab will be well tolerated and will result
      in greater reduction of LDL-C than ezetimibe, defined by the mean percent change from
      baseline at Weeks 22 and 24 of Part B and percent change from baseline at Week 24 of Part B,
      in statin-intolerant hypercholesterolemic subjects.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT01984424</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>MD</name>
      <address>Amgen</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>